MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
Two-year collaboration aims to strengthen primary healthcare systems, generate real-world evidence, and support responsible adoption of AI and digital health technologies across South-East Asia
Developed by the Sudha Gopalakrishnan Brain Centre, the publicly accessible ANCHOR atlas maps over 200 brainstem structures at cellular resolution, offering new possibilities for neuroscience research and clinical applications
Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
The launch comes against the backdrop of a significant public health burden
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
